The part 3 OVAL scientific trial has been discontinued after the mixture of ofranergene obadenovec and paclitaxel didn't obtain the research’s major finish factors of enchancment in progression-free and total survival.The use of ofra-vec (ofranergene obadenovec; VB-111) with paclitaxel as...